Abstract Body

We know that PrEP is protective and recommended for HIV prevention across populations, with good tolerability and very few safety risks. So what are the remaining controversies that are challenging us as we head towards PrEP scale-up? This talk will tackle five of the debates currently raging: (1) The potential impact of PrEP as a safer conception measure; (2) The time to protection at different mucosal surfaces; (3) PrEP isn’t an option in adolescent populations; (4); There isn’t sexual disinhibition with PrEP; (5) PrEP can be cost-effective especially when used intermittently? Are these controversies real? Are they myths? What is the known evidence?